The CF Foundation announced that Bruce Marshall, MD, chief medical officer, will retire from his role as of July 1, 2024. Marshall has dedicated much of his career to cystic fibrosis, with nearly 22 years spent leading the clinical affairs department at the Foundation during a time of profound change and groundbreaking progress. 

“We are so grateful for Bruce’s transformative leadership and the incredible impact his contributions have had on the CF community,” said Michael Boyle, MD, president and chief executive officer of the CF Foundation. “He has built an impressive team deeply focused on improving the lives of people with CF by advancing the high-quality, specialized care they experience through our care center network.” 

Throughout his tenure, Marshall has overseen activities related to clinical care for the Foundation, including the care center network, quality improvement initiatives, clinical practice guidelines, and more. He was instrumental in launching the CF Foundation Patient Registry in 2010, which has resulted in more than 250 research publications and serves as a resource that continues to assist research coordinators in identifying potential candidates for clinical trials. Under his leadership, the clinical affairs team has been successful in recruiting, developing, and retaining new CF care team members while continually refining and improving the accreditation process for care centers.  

“It's been an honor to have worked alongside such dedicated colleagues and to have played a part in the remarkable story that is cystic fibrosis,” said Marshall. “I am confident that the talented team at the Foundation will continue making progress in evolving how we provide care to the CF community so that one day, every person with CF has the opportunity to lead a long, fulfilling life.”  

Also on July 1, Albert Faro, MD, who currently serves as vice president of clinical affairs, will succeed Marshall as the Foundation’s next chief medical officer. Whitney Brown, MD, who currently serves as senior director, clinical affairs, will expand her portfolio and become vice president, clinical affairs, reporting to Faro. Marshall will continue serving the Foundation as an advisor, helping to ensure a smooth transition and contributing to key initiatives such as the evolution of the care model and the next generation patient registry.